Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Development of Prostate Cancer Stereotactic Radiotherapy in Tampere Using Intra-fractional Movement Detector and Diffusion-weighted Magnetic Resonance Imaging.

NCT02319239 is registered in ClinicalTrials.gov with Tampere University Hospital as lead sponsor.

NCT NCT02319239
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02319239 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Development of Prostate Cancer Stereotactic Radiotherapy in Tampere Using Intra-fractional Movement Detector and Diffusion-weighted Magnetic Resonance Imaging.
Lead sponsor
Tampere University Hospital
Phase
Not applicable
Overall status
Completed
Start date
May 31, 2014
Completion date
October 31, 2020
Enrollment
80 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate neoplasms, toxicity due to radiotherapy